Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria

J. A. Sherwood, C. N. Oster, M. Adoyo-Adoyo, John C Beier, G. S. Gachihi, P. M. Nyakundi, W. R. Ballou, A. D. Brandling-Bennett, I. K. Schwartz, J. B O Were, R. A. Wirtz, I. Schneider, C. R. Roberts, J. F. Young, M. Gross, J. D. Chulay

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recombinant sporozoite vaccine or placebo were administered once to 25 volunteers from an area endemic for malaria. Antibody to R32tet32 rose in 9 of 15 receiving vaccine and remained elevated in 6 for 6 months. Mean absorbance increase was 0·43 ± 0·40 with vaccine, 0·01 ± 0·23 with placebo, and 0·72 ± 0·19 in responders. Six non-responders had significantly lower pre-immunization levels (0·07 ± 0·05) than responders (0·39 ± 0·25). There was an association between an increase in immunofluorescence (n = 4) and an increase in absorbence (n = 9) among vaccine recipients (n = 15). Vaccine-induced increase in antibody to natural circumsporozoite antigen was indicated by increases in immunofluorescence and by increases in circumsporozoite precipitation score in 2 of the 5 responders with highest antibody increase measured by enzyme-linked immunosorbent assay. Response to subunit sporozoite vaccine paralleled response to prior natural sporozoite exposure and was significant and prolonged in a population with prior natural exposure to malaria.

Original languageEnglish
Pages (from-to)336-340
Number of pages5
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume85
Issue number3
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Sporozoites
Plasmodium falciparum
Malaria
Antibody Formation
Vaccines
Safety
Population
Fluorescent Antibody Technique
Antibodies
Placebos
Synthetic Vaccines
Subunit Vaccines
Volunteers
Immunization
Enzyme-Linked Immunosorbent Assay
Antigens

ASJC Scopus subject areas

  • Parasitology
  • Medicine(all)

Cite this

Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine : boosting of antibody response in a population with prior natural exposure to malaria. / Sherwood, J. A.; Oster, C. N.; Adoyo-Adoyo, M.; Beier, John C; Gachihi, G. S.; Nyakundi, P. M.; Ballou, W. R.; Brandling-Bennett, A. D.; Schwartz, I. K.; Were, J. B O; Wirtz, R. A.; Schneider, I.; Roberts, C. R.; Young, J. F.; Gross, M.; Chulay, J. D.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 85, No. 3, 01.01.1991, p. 336-340.

Research output: Contribution to journalArticle

Sherwood, JA, Oster, CN, Adoyo-Adoyo, M, Beier, JC, Gachihi, GS, Nyakundi, PM, Ballou, WR, Brandling-Bennett, AD, Schwartz, IK, Were, JBO, Wirtz, RA, Schneider, I, Roberts, CR, Young, JF, Gross, M & Chulay, JD 1991, 'Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria', Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 85, no. 3, pp. 336-340. https://doi.org/10.1016/0035-9203(91)90281-3
Sherwood, J. A. ; Oster, C. N. ; Adoyo-Adoyo, M. ; Beier, John C ; Gachihi, G. S. ; Nyakundi, P. M. ; Ballou, W. R. ; Brandling-Bennett, A. D. ; Schwartz, I. K. ; Were, J. B O ; Wirtz, R. A. ; Schneider, I. ; Roberts, C. R. ; Young, J. F. ; Gross, M. ; Chulay, J. D. / Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine : boosting of antibody response in a population with prior natural exposure to malaria. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 1991 ; Vol. 85, No. 3. pp. 336-340.
@article{3bc04a9a1aac4bd7822be1db0c5cef82,
title = "Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria",
abstract = "Recombinant sporozoite vaccine or placebo were administered once to 25 volunteers from an area endemic for malaria. Antibody to R32tet32 rose in 9 of 15 receiving vaccine and remained elevated in 6 for 6 months. Mean absorbance increase was 0·43 ± 0·40 with vaccine, 0·01 ± 0·23 with placebo, and 0·72 ± 0·19 in responders. Six non-responders had significantly lower pre-immunization levels (0·07 ± 0·05) than responders (0·39 ± 0·25). There was an association between an increase in immunofluorescence (n = 4) and an increase in absorbence (n = 9) among vaccine recipients (n = 15). Vaccine-induced increase in antibody to natural circumsporozoite antigen was indicated by increases in immunofluorescence and by increases in circumsporozoite precipitation score in 2 of the 5 responders with highest antibody increase measured by enzyme-linked immunosorbent assay. Response to subunit sporozoite vaccine paralleled response to prior natural sporozoite exposure and was significant and prolonged in a population with prior natural exposure to malaria.",
author = "Sherwood, {J. A.} and Oster, {C. N.} and M. Adoyo-Adoyo and Beier, {John C} and Gachihi, {G. S.} and Nyakundi, {P. M.} and Ballou, {W. R.} and Brandling-Bennett, {A. D.} and Schwartz, {I. K.} and Were, {J. B O} and Wirtz, {R. A.} and I. Schneider and Roberts, {C. R.} and Young, {J. F.} and M. Gross and Chulay, {J. D.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0035-9203(91)90281-3",
language = "English",
volume = "85",
pages = "336--340",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine

T2 - boosting of antibody response in a population with prior natural exposure to malaria

AU - Sherwood, J. A.

AU - Oster, C. N.

AU - Adoyo-Adoyo, M.

AU - Beier, John C

AU - Gachihi, G. S.

AU - Nyakundi, P. M.

AU - Ballou, W. R.

AU - Brandling-Bennett, A. D.

AU - Schwartz, I. K.

AU - Were, J. B O

AU - Wirtz, R. A.

AU - Schneider, I.

AU - Roberts, C. R.

AU - Young, J. F.

AU - Gross, M.

AU - Chulay, J. D.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Recombinant sporozoite vaccine or placebo were administered once to 25 volunteers from an area endemic for malaria. Antibody to R32tet32 rose in 9 of 15 receiving vaccine and remained elevated in 6 for 6 months. Mean absorbance increase was 0·43 ± 0·40 with vaccine, 0·01 ± 0·23 with placebo, and 0·72 ± 0·19 in responders. Six non-responders had significantly lower pre-immunization levels (0·07 ± 0·05) than responders (0·39 ± 0·25). There was an association between an increase in immunofluorescence (n = 4) and an increase in absorbence (n = 9) among vaccine recipients (n = 15). Vaccine-induced increase in antibody to natural circumsporozoite antigen was indicated by increases in immunofluorescence and by increases in circumsporozoite precipitation score in 2 of the 5 responders with highest antibody increase measured by enzyme-linked immunosorbent assay. Response to subunit sporozoite vaccine paralleled response to prior natural sporozoite exposure and was significant and prolonged in a population with prior natural exposure to malaria.

AB - Recombinant sporozoite vaccine or placebo were administered once to 25 volunteers from an area endemic for malaria. Antibody to R32tet32 rose in 9 of 15 receiving vaccine and remained elevated in 6 for 6 months. Mean absorbance increase was 0·43 ± 0·40 with vaccine, 0·01 ± 0·23 with placebo, and 0·72 ± 0·19 in responders. Six non-responders had significantly lower pre-immunization levels (0·07 ± 0·05) than responders (0·39 ± 0·25). There was an association between an increase in immunofluorescence (n = 4) and an increase in absorbence (n = 9) among vaccine recipients (n = 15). Vaccine-induced increase in antibody to natural circumsporozoite antigen was indicated by increases in immunofluorescence and by increases in circumsporozoite precipitation score in 2 of the 5 responders with highest antibody increase measured by enzyme-linked immunosorbent assay. Response to subunit sporozoite vaccine paralleled response to prior natural sporozoite exposure and was significant and prolonged in a population with prior natural exposure to malaria.

UR - http://www.scopus.com/inward/record.url?scp=0025892669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025892669&partnerID=8YFLogxK

U2 - 10.1016/0035-9203(91)90281-3

DO - 10.1016/0035-9203(91)90281-3

M3 - Article

C2 - 1949134

AN - SCOPUS:0025892669

VL - 85

SP - 336

EP - 340

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 3

ER -